Figure 3

Pretreatment with EPA or DHA prevents the doxorubicin-induced decrease in UCP2 mRNA levels. H9C2 cells were (i) left untreated or (ii) treated with 100 μM EPA or 50 μM DHA for 24 h, then treated with 1 μM doxorubicin for 24 h or (iii) treated with 1 μM doxorubicin (DOX) in the absence or presence of 100 μM EPA or 50 μM DHA for 24 h, then UCP2 mRNA levels were measured by reverse transcription and quantitative real-time PCR, with GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as the internal control. The results are expressed relative to the untreated control value and are the mean ± S.D. for three independent experiments. ***: p <0005 compared to the untreated control; ^##, ^{# # #}: p <0.01 and p <0.001 compared to doxorubicin treatment alone, respectively.